|
1
|
Levine M: Treatment of thrombotic
disorders in cancer patients. Haemostasis. 27 (Suppl 1):38–43.
1997.PubMed/NCBI
|
|
2
|
Carrier M, Khorana AA, Moretto P, Le Gal
G, Karp R and Zwicker JI: Lack of evidence to support
thromboprophylaxis in hospitalized medical patients with cancer. Am
J Med. 127:82–6.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moheimani F and Jackson DE: Venous
thromboembolism: Classification, risk factors, diagnosis, and
management. ISRN Hematol. 2011:1246102011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alikhan R, Cohen AT, Combe S, Samama MM,
Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG and
Turpie AG; MEDENOX Study, : Risk factors for venous thromboembolism
in hospitalized patients with acute medical illness: Analysis of
the MEDENOX Study. Arch Intern Med. 164:963–968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Rooden CJ, Schippers EF, Barge RM,
Rosendaal FR, Guiot HF, van der Meer FJ, Meinders AE and Huisman
MV: Infectious complications of central venous catheters increase
the risk of catheter-related thrombosis in hematology patients: A
prospective study. J Clin Oncol. 23:2655–2660. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kenneth AB: Drug-induced thrombosis in
patients with malignancy. UpToDate. 2017, https://www.uptodate.comJanuary 7–2019
|
|
7
|
O'Connell CL, Boswell WD, Duddalwar V,
Caton A, Mark LS, Vigen C and Liebman HA: Unsuspected pulmonary
emboli in cancer patients: Clinical correlates and relevance. J
Clin Oncol. 24:4928–4932. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sørensen HT, Mellemkjaer L, Olsen JH and
Baron JA: Prognosis of cancers associated with venous
thromboembolism. N Engl J Med. 343:1846–1850. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chew HK, Wun T, Harvey D, Zhou H and White
RH: Incidence of venous thromboembolism and its effect on survival
among patients with common cancers. Arch Intern Med. 166:458–464.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gross CP, Galusha DH and Krumholz HM: The
impact of venous thromboembolism on risk of death or hemorrhage in
older cancer patients. J Gen Intern Med. 22:321–326. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hultcrantz M, Björkholm M, Dickman PW,
Landgren O, Derolf ÅR, Kristinsson SY and Andersson TML: Risk for
arterial and venous thrombosis in patients with myeloproliferative
neoplasms: A population-based cohort study. Ann Intern Med.
168:317–325. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elting LS, Escalante CP, Cooksley C,
Avritscher EB, Kurtin D, Hamblin L, Khosla SG and Rivera E:
Outcomes and cost of deep venous thrombosis among patients with
cancer. Arch Intern Med. 164:1653–1661. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walker AJ, Card TR, West J, Crooks C and
Grainge MJ: Incidence of venous thromboembolism in patients with
cancer - a cohort study using linked United Kingdom databases. Eur
J Cancer. 49:1404–1413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stein PD, Beemath A, Meyers FA, Skaf E,
Sanchez J and Olson RE: Incidence of venous thromboembolism in
patients hospitalized with cancer. Am J Med. 119:60–68. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khorana AA, Francis CW, Culakova E,
Kuderer NM and Lyman GH: Frequency, risk factors, and trends for
venous thromboembolism among hospitalized cancer patients. Cancer.
110:2339–2346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen AT, Katholing A, Rietbrock S, Bamber
L and Martinez C: Epidemiology of first and recurrent venous
thromboembolism in patients with active cancer. A population-based
cohort study. Thromb Haemost. 117:57–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kenneth AB: Pathogenesis of the
hypercoagulable state associated with malignancy. UpToDate. 2017,
https://www.uptodate.comJanuary
9–2019
|
|
18
|
van Doormaal FF, Raskob GE, Davidson BL,
Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH and Büller
HR: Treatment of venous thromboembolism in patients with cancer:
Subgroup analysis of the Matisse clinical trials. Thromb Haemost.
101:762–769. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kearon C, Akl EA, Ornelas J, Blaivas A,
Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et
al: Antithrombotic therapy for VTE disease. Chest. 149:315–352.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lyman GH, Bohlke K, Khorana AA, Kuderer
NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis
CW, et al American Society of Clinical Oncology, : Venous
thromboembolism prophylaxis and treatment in patients with cancer:
American society of clinical oncology clinical practice guideline
update 2014. J Clin Oncol. 33:654–656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Francis CW, Kessler CM, Goldhaber SZ,
Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL,
Spyropoulos AC, et al: Treatment of venous thromboembolism in
cancer patients with dalteparin for up to 12 months: The DALTECAN
Study. J Thromb Haemost. 13:1028–1035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Streiff MB, Holmstrom B, Angelini D,
Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB,
Fogerty AE, Gao S, et al: NCCN Guidelines insights:
Cancer-associated venous thromboembolic disease, Version 2.2018. J
Natl Compr Canc Netw. 16:1289–1303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kahale LA, Hakoum MB, Tsolakian IG, Matar
CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H and
Akl EA: Anticoagulation for the long-term treatment of venous
thromboembolism in people with cancer. Cochrane Database Syst Rev.
6:CD0066502018.PubMed/NCBI
|
|
24
|
Lee AY, Levine MN, Baker RI, Bowden C,
Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et
al Randomized comparison of low-molecular-weight heparin versus
oral anticoagulant therapy for the prevention of recurrent venous
thromboembolism in patients with cancer (CLOT) Investigators, :
Low-molecular-weight heparin versus a coumarin for the prevention
of recurrent venous thromboembolism in patients with cancer. N Engl
J Med. 349:146–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meyer G, Marjanovic Z, Valcke J, Lorcerie
B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P and
Farge D: Comparison of low-molecular-weight heparin and warfarin
for the secondary prevention of venous thromboembolism in patients
with cancer: A randomized controlled study. Arch Intern Med.
162:1729–1735. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deitcher SR, Kessler CM, Merli G, Rigas
JR, Lyons RM and Fareed J; ONCENOX Investigators, : Secondary
prevention of venous thromboembolic events in patients with active
cancer: Enoxaparin alone versus initial enoxaparin followed by
warfarin for a 180-day period. Clin Appl Thromb Hemost. 12:389–396.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee AYY, Kamphuisen PW, Meyer G,
Bauersachs R, Janas MS, Jarner MF and Khorana AA; CATCH
Investigators, : Tinzaparin vs warfarin for treatment of acute
venous thromboembolism in patients with active cancer. A randomized
clinical trial. JAMA. 314:677–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hull RD, Pineo GF, Brant RF, Mah AF, Burke
N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, et al LITE Trial
Investigators, : Long-term low-molecular-weight heparin versus
usual care in proximal-vein thrombosis patients with cancer. Am J
Med. 119:1062–1072. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harrison L, McGinnis J, Crowther M,
Ginsberg J and Hirsh J: Assessment of outpatient treatment of
deep-vein thrombosis with low-molecular-weight heparin. Arch Intern
Med. 158:2001–2003. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rose AJ, Sharman JP, Ozonoff A, Henault LE
and Hylek EM: Effectiveness of warfarin among patients with cancer.
J Gen Intern Med. 22:997–1002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khorana AA, Noble S, Lee AYY, Soff G,
Meyer G, O'Connell C and Carrier M: Role of direct oral
anticoagulants in the treatment of cancer-associated venous
thromboembolism: Guidance from the SSC of the ISTH. J Thromb
Haemost. 16:1891–1894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prins MH, Lensing AW, Bauersachs R, van
Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL,
Decousus H, Raskob GE, et al EINSTEIN Investigators, : Oral
rivaroxaban versus standard therapy for the treatment of
symptomatic venous thromboembolism: A pooled analysis of the
EINSTEIN-DVT and PE randomized studies. Thromb J. 11:212013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schulman S, Goldhaber SZ, Kearon C, Kakkar
AK, Schellong S, Eriksson H, Hantel S, Feuring M and Kreuzer J:
Treatment with dabigatran or warfarin in patients with venous
thromboembolism and cancer. Thromb Haemost. 114:150–157. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vedovati MC, Germini F, Agnelli G and
Becattini C: Direct oral anticoagulants in patients with VTE and
cancer: A systematic review and meta-analysis. Chest. 147:475–483.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agnelli G, Buller HR, Cohen A, Gallus AS,
Lee TC, Pak R, Raskob GE, Weitz JI and Yamabe T: Oral apixaban for
the treatment of venous thromboembolism in cancer patients: Results
from the AMPLIFY trial. J Thromb Haemost. 13:2187–2191. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Prisco D, Tufano A, Cenci C, Pignatelli P,
Santilli F, Di Minno G and Perticone F: Position paper of the
Italian Society of Internal Medicine (SIMI) on prophylaxis and
treatment of venous thromboembolism in patients with cancer. Intern
Emerg Med. 14:21–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
https://clinicaltrials.gov/ct2/show/NCT02744092April
20–2016
|
|
38
|
https://clinicaltrials.gov/ct2/show/NCT03240120August
4–2017
|
|
39
|
https://clinicaltrials.gov/ct2/show/NCT03045406February
7–2017
|
|
40
|
https://clinicaltrials.gov/ct2/show/NCT02581176October
20–2015
|
|
41
|
Raskob GE, van Es N, Verhamme P, Carrier
M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri
MF, et al Hokusai VTE Cancer Investigators, : Edoxaban for the
treatment of cancer-associated venous thromboembolism. N Engl J
Med. 378:615–624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Young AM, Marshall A, Thirlwall J, Chapman
O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, et
al: Comparison of an oral factor Xa inhibitor with low molecular
weight heparin in patients with cancer with venous thromboembolism:
Results of a randomized trial (SELECT-D). J Clin Oncol.
36:2017–2023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
https://clinicaltrials.gov/ct2/show/NCT03139487May
4–2017
|
|
44
|
https://clinicaltrials.gov/ct2/show/NCT02746185April
21–2016
|
|
45
|
https://clinicaltrials.gov/ct2/show/NCT02583191October
22–2015
|
|
46
|
Hakoum MB, Kahale LA, Tsolakian IG, Matar
CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H and
Akl EA: Anticoagulation for the initial treatment of venous
thromboembolism in people with cancer. Cochrane Database Syst Rev.
1:CD0066492018.PubMed/NCBI
|
|
47
|
Cohen AT, Spiro TE, Büller HR, Haskell L,
Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, et
al MAGELLAN Investigators, : Rivaroxaban for thromboprophylaxis in
acutely ill medical patients. N Engl J Med. 368:513–523. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Akl EA, van Doormaal FF, Barba M, Kamath
G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO and
Schünemann HJ: Parenteral anticoagulation may prolong the survival
of patients with limited small cell lung cancer: A Cochrane
systematic review. J Exp Clin Cancer Res. 27:42008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
van Doormaal FF, Di Nisio M, Otten HM,
Richel DJ, Prins M and Buller HR: Randomized trial of the effect of
the low molecular weight heparin nadroparin on survival in patients
with cancer. J Clin Oncol. 29:2071–2076. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yhim HY, Choi WI, Kim SH, Nam SH, Kim KH,
Mun YC, Oh D, Hwang HG, Lee KW, Song EK, et al: Long-term
rivaroxaban for the treatment of acute venous thromboembolism in
patients with active cancer in a prospective multicenter trial.
Blood J. 130:37112017.
|
|
51
|
https://clinicaltrials.gov/ct2/show/NCT03214172July
11–2017
|
|
52
|
https://clinicaltrials.gov/ct2/show/NCT02742623April
19–2016
|
|
53
|
https://clinicaltrials.gov/ct2/show/NCT01989845November
21–2013
|
|
54
|
https://clinicaltrials.gov/ct2/show/NCT03692065October
2–2018
|
|
55
|
https://clinicaltrials.gov/ct2/show/NCT02585713October
23–2015
|
|
56
|
Trujillo-Santos J, Nieto JA, Tiberio G,
Piccioli A, Di Micco P, Prandoni P, Monreal M and Registry RIETE;
RIETE Registry, : Predicting recurrences or major bleeding in
cancer patients with venous thromboembolism. Findings from the
RIETE Registry. Thromb Haemost. 100:435–439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hutten BA, Prins MH, Gent M, Ginsberg J,
Tijssen JG and Büller HR: Incidence of recurrent thromboembolic and
bleeding complications among patients with venous thromboembolism
in relation to both malignancy and achieved international
normalized ratio: A retrospective analysis. J Clin Oncol.
18:3078–3083. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lyman GH, Khorana AA, Kuderer NM, Lee AY,
Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates
LE, et al American Society of Clinical Oncology Clinical Practice,
: Venous thromboembolism prophylaxis and treatment in patients with
cancer: American Society of Clinical Oncology clinical practice
guideline update. J Clin Oncol. 31:2189–2204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Agnelli G, George DJ, Kakkar AK, Fisher W,
Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F and Turpie
AG; SAVE-ONCO Investigators, : Semuloparin for thromboprophylaxis
in patients receiving chemotherapy for cancer. N Engl J Med.
366:601–609. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Maraveyas A, Waters J, Roy R, Fyfe D,
Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C,
et al: Gemcitabine versus gemcitabine plus dalteparin
thromboprophylaxis in pancreatic cancer. Eur J Cancer.
48:1283–1292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Agnelli G, Gussoni G, Bianchini C, Verso
M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G,
et al PROTECHT Investigators, : Nadroparin for the prevention of
thromboembolic events in ambulatory patients with metastatic or
locally advanced solid cancer receiving chemotherapy: A randomised,
placebo-controlled, double-blind study. Lancet Oncol. 10:943–949.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
https://clinicaltrials.gov/ct2/show/NCT02048865January
29–2014
|
|
63
|
https://clinicaltrials.gov/ct2/show/NCT02555878September
22–2015
|
|
64
|
Walenga JM and Adiguzel C: Drug and
dietary interactions of the new and emerging oral anticoagulants.
Int J Clin Pract. 64:956–967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lohr LK: Drug interactions with newer oral
chemotherapy agents. US Pharm. 34 (Oncology suppl):4–8. 2009.
|
|
66
|
Neagu M, Caruntu C, Constantin C, Boda D,
Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin
carcinogenesis: Updates in experimental models (Review). Oncol Rep.
35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Voiculescu VM, Caruntu C, Solomon I, Lupu
M, Ilie MA, Boda D, et al: Squamous cell carcinoma: biomarkers and
potential therapeutic targetsHuman Skin Cancers-Pathways,
Mechanisms, Targets and Treatments. IntechOpen; London: pp.
135–159. 2018
|
|
68
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non-melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Boda D, Docea AO, Calina D, Ilie MA,
Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE,
Voiculescu V, et al: Human papilloma virus: Apprehending the link
with carcinogenesis and unveiling new research avenues (Review).
Int J Oncol. 52:637–655. 2018.PubMed/NCBI
|
|
70
|
Popescu R, Bratu O, Spinu D, Marcu D,
Farcas C, Dinu M and Mischianu D: Neuroendocrine differentiation in
prostate cancer – a review. Rom J Mil Med. 118:16–19. 2015.
|
|
71
|
Marcu D, Spinu D, Mischianu D, Socea B,
Oprea I and Bratu O: Oncological follow-up after radical
prostatectomy. Rom J Mil Med. 120:39–42. 2017.
|
|
72
|
Radulescu A, Madan V, Aungurenci A, Bratu
O, Farcas C, Dinu M and Mischianu D: Antibiotic resistant urinary
tract infections in an urology ward. Rom J Mil Med. 118:20–22.
2015.
|
|
73
|
Spinu D, Bratu O, Popescu R, Marcu D,
Radulescu A and Mischianu D: Clostridium difficile-an emerging
plague. Rom J Mil Med. 118:12–15. 2015.
|
|
74
|
Socea LI, Visan DC, Barbuceanu SF, Apostol
TV, Bratu OG and Bogdan S: The antioxidant activity of some
acylhydrazones with dibenzo[a,d][7]annulene moiety. Rev Chim
Buchar. 69:795–797. 2018.
|
|
75
|
https://clinicaltrials.gov/ct2/show/NCT01444612October
3–2011
|
|
76
|
https://clinicaltrials.gov/ct2/show/NCT00219973September
22–2005
|
|
77
|
https://clinicaltrials.gov/ct2/show/NCT02366871February
19–2015
|
|
78
|
Perry JR, Julian JA, Laperriere NJ, Geerts
W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A,
et al: PRODIGE: A randomized placebo-controlled trial of dalteparin
low-molecular-weight heparin thromboprophylaxis in patients with
newly diagnosed malignant glioma. J Thromb Haemost. 8:1959–1965.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Solomon I, Voiculescu VM, Caruntu C, Lupu
M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C,
et al: Neuroendocrine factors and head and neck squamous cell
carcinoma: An affair to remember. Dis Markers. 2018:97878312018.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
|
|
81
|
Marras LC, Geerts WH and Perry JR: The
risk of venous thromboembolism is increased throughout the course
of malignant glioma: An evidence-based review. Cancer. 89:640–646.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–24. 2011. View Article : Google Scholar
|
|
83
|
Lupu M, Caruntu A, Caruntu C, Boda D,
Moraru L, Voiculescu V and Bastian A: Non-invasive imaging of
actinic cheilitis and squamous cell carcinoma of the lip. Mol Clin
Oncol. 8:640–646. 2018.PubMed/NCBI
|
|
84
|
Herishanu Y, Misgav M, Kirgner I, Ben-Tal
O, Eldor A and Naparstek E: Enoxaparin can be used safely in
patients with severe thrombocytopenia due to intensive chemotherapy
regimens. Leuk Lymphoma. 45:1407–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ibrahim RB, Skewes MD and Kuriakose P:
‘Sailing in troubled waters’: A review of the use of
anticoagulation in adult cancer patients with thrombocytopenia.
Blood Coagul Fibrinolysis. 27:615–630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Stopa JD, Neuberg D, Puligandla M, Furie
B, Flaumenhaft R and Zwicker JI: Protein disulfide isomerase
inhibition blocks thrombin generation in humans by interfering with
platelet factor V activation. JCI Insight. 2:e893732017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zwicker JI, Schlechter BL, Stopa JD,
Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA,
Kuemmerle N, Wong E, et al CATIQ Investigators 11, : Targeting
protein disulfide isomerase with the flavonoid isoquercetin to
improve hypercoagulability in advanced cancer. JCI Insight.
4(ii)2019.PubMed/NCBI
|
|
88
|
https://clinicaltrials.gov/ct2/show/NCT02195232July
21–2014
|
|
89
|
Tica OA, Tica O, Antal L, Hatos A, Popescu
MI, Pantea Stoian A, Bratu OG, Gaman MA, Pituru SM and Diaconu CC:
Modern oral anticoagulant treatment in patients with atrial
fibrillation and heart failure: Insights from the clinical
practice. Farmacia. 66:972–976. 2018. View Article : Google Scholar
|
|
90
|
https://clinicaltrials.gov/ct2/show/NCT01524653February
2–2012
|
